Articles tagged with Colorectal Cancer
A University of Oklahoma researcher has been awarded a NIH grant to evaluate thousands of natural products with therapeutic potential. The goal is to identify specific components of these products that have anticancer properties and understand how they work.
Researchers found that CHEK2 variants do not increase colorectal cancer risk compared to controls. Three low-risk missense variants were identified as potential drivers of breast cancer risk variability.
A new treatment approach has been confirmed effective in a major study, showing that locally advanced rectal cancer patients can experience complete tumour disappearance without needing surgery. This method reduces the risk of recurrence and preserves normal bowel function, offering a promising alternative to traditional treatments.
The study analyzes six major digestive system cancers worldwide and in China, revealing correlations between country HDI and cancer prevalence. Colorectal cancer is the most prevalent, while Asia accounts for 60.5% of new gastrointestinal cancer cases globally.
Researchers discuss the role of gut microbiota in regulating basal inflammation levels and promoting healing of the bowel after surgery. Weakened gut barrier function may lead to persistent low-grade inflammation and increased risk of cancer recurrence.
A new Cleveland Clinic study reveals that diet-derived molecules called metabolites are the main drivers of young-onset colorectal cancer risk, particularly those associated with red and processed meat. The research suggests that addressing diet with doctors can help prevent colon cancer in younger adults.
A clinical trial in Denmark found that offering women further screening opportunities during breast cancer screenings significantly increased their participation and enabled early diagnosis of other cancers. The study used a cluster-randomized crossover design and involved over 27,000 participants.
The study identified 96 mutated driver genes, 9 of which were previously unknown in CRC, and 24 that were new to any form of cancer. A new molecular classifier system was developed, identifying five distinct CRC prognostic subtypes with unique molecular characteristics.
Researchers discuss diverse BRAF alterations found in human cancers and strategies to inhibit them. Class I BRAF inhibitors represent a landmark achievement in precision oncology, with FDA-approved dabrafenib/trametinib for metastatic BRAF p.V600E-mutant solid tumors.
A cohort study found that aspirin use was associated with a greater absolute reduction in risk of colorectal cancer among individuals with less healthy lifestyles. Lifestyle risk factors may help identify those with a more favorable risk-benefit profile for cancer prevention with aspirin.
A study published in JAMA Oncology found that regular aspirin use significantly lowers the risk of colorectal cancer in individuals with higher lifestyle-related risk factors. The benefits were most pronounced among those with unhealthiest lifestyles, where treating 78 patients with aspirin would prevent one case of colorectal cancer o...
Researchers identified areas with lower colorectal cancer screening rates and developed an interactive web map to pinpoint neighborhood-level disparities. The study aims to inform targeted education or intervention programs, ultimately increasing screening rates in priority neighborhoods and contributing to national improvements.
A new AI algorithm assesses immune cells in early-stage bowel cancer tumours to predict recurrence risk. The CD3 Score test has been shown to reliably identify high-risk cancers that are more likely to recur within five years of surgery, enabling clinicians to make informed decisions about chemotherapy treatment.
A study published in JAMA Surgery shows that liver transplants significantly improve progression-free survival rates for patients with unresectable colorectal liver metastases compared to other therapies. At three years, 90% of transplant patients remained cancer-progression free, whereas only 42% of those receiving alternative treatme...
A new study published in JAMA Network Open shows that an at-home fecal immunochemical testing (FIT) screen can reduce the risk of colorectal cancer death by 33%, comparable to screening colonoscopy. FIT is a non-invasive test that involves mailing a stool sample to the laboratory for analysis.
Cancer cells can attach themselves to liver cells when specific proteins are present, allowing them to colonize and form new tumors. This discovery provides insights into the metastatic process and may lead to potential treatments that prevent cancer from establishing new tumors.
Researchers found that eliminating racial disparities in follow-up colonoscopy rates and quality would significantly reduce colorectal cancer incidence and mortality. By closing these gaps, the study aims to achieve health equity and find innovative solutions for true change.
Colorectal cancer treatment is limited by existing therapies, but epigenetic modifiers offer a novel approach. DNMT and TET inhibitors have been identified as promising therapeutic strategies to restore normal gene function and combat CRC.
A nested case-control study found that completing fecal immunochemical tests lowers overall death risk from colorectal cancer, particularly in the left colon. The association was observed across racial and ethnic groups, supporting its use in population-based screening strategies.
Researchers have identified a potential biomarker, CXCL13, that correlates with treatment response and prognosis in patients with metastatic colorectal cancer. High levels of CXCL13 are associated with positive treatment response and improved survival, while low levels indicate non-response and poorer prognosis.
Researchers found that regorafenib synergizes with TAS102 to inhibit cancer growth, angiogenesis, and microvessel density in preclinical models of colorectal and gastric cancers. The combination also suppresses ERK1/2 activation regardless of KRAS or BRAF mutational status.
The study confirms the effectiveness of 12 standards in reducing hospital length of stay, costs, and complication rates. Standardized care protocols across multiple phases of surgical care lead to improved patient outcomes and hospital efficiency.
Cutting processed meat intake by 30% reduces the risk of diabetes, cardiovascular disease, and colorectal cancer. The study found that this reduction would lead to over 350,000 fewer diabetes cases and tens of thousands fewer cardiovascular disease and colorectal cancer cases.
African American woman breast cancer survivor talking about her experience with breast cancer and the impact of breast cancer on women's lives. The American Cancer Society is a leading organization in cancer research, patient services, and advocacy.
Immunotherapy has emerged as a promising approach in treating metastatic colorectal cancer, especially for patients with dMMR/MSI-H tumors. The use of immune checkpoint inhibitors has shown favorable outcomes in clinical trials, including improved progression-free survival and disease control rates.
Researchers have identified a new potential target for colorectal cancer treatment in the form of the protein PFDN6. Studies found that PFDN6 levels are increased in CRC patients, contributing to tumor growth and cell migration. Reducing PFDN6 in lab studies slowed cancer cell spread and increased cell death.
AlphaFold's groundbreaking ability to predict protein structures is set to transform predictive medicine, enabling the development of personalized vaccines and adaptive clinical trials. However, the review also highlights crucial challenges and ethical considerations surrounding AI integration with clinical data.
Researchers at NTNU have developed a way to reconstruct 3D models of the colon using single images taken by capsule endoscopy cameras. These models can aid in detecting abnormalities and signs of disease, enabling specialists to make diagnoses faster.
Researchers at Virginia Tech have discovered a possible new pathway to treat colorectal cancer by targeting the NF-kB-inducing kinase (NIK) protein. The study, led by Irving Coy Allen, identifies changes in a significant signaling pathway in human patients and presents potential targets for therapeutics.
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
Researchers at Weill Cornell Medicine developed an artificial intelligence-powered method for detecting tumor DNA in blood, showing high sensitivity and accuracy in predicting cancer recurrence. The technology, called MRD-EDGE, can detect subtle patterns in sequencing data to distinguish between cancer and non-cancerous signals.
Researchers from IBEC investigated how mechanical properties of colorectal cancer stem cells influence metastasis. Cells expressing LGR5 protein exhibit softer, less sticky properties and better adhere to blood vessel walls.
Researchers developed an oral inulin-based hydrogel targeting colorectal tumors, which released oxaliplatin and modulated the microbiota to generate anti-tumor immune responses. The treatment showed improved chemotherapy efficacy and reduced tumor progression.
Researchers have developed a novel approach to treat colorectal cancer using simultaneous delivery of alpha- and beta-radionuclides, significantly reducing side effects. The therapy, known as pretargeted dual-isotope radionuclide therapy, has been shown to be effective in inducing tumor shrinkage and cures.
Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.
A recent NTU Singapore study found that eight in ten gastroenterologists accept and trust the use of AI-powered tools in diagnosing and assessing colorectal polyps. The study, which surveyed 165 doctors in the Asia-Pacific region, also found that more experienced gastroenterologists perceived a lower risk of AI tools.
This study found that lowering the fecal immunochemical test positivity threshold can achieve comparable sensitivity and specificity to the multitarget stool RNA test without additional testing. The findings are similar to previous observations with multitarget stool DNA testing, suggesting a potentially simpler screening method.
Research led by Weill Cornell Medicine found that most colorectal cancers begin with the loss of intestinal stem cells, even before cancer-causing genetic alterations appear. This new understanding suggests a unified model for colorectal cancer initiation where damage to intestinal crypts causes a decrease in aPKC protein expression.
A study by UCLA Health Jonsson Comprehensive Cancer Center researchers found that combining experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer. The median progression-free survival was 6.2 months compared to 2.1 months f...
A Kaiser Permanente study of 316,443 patients reveals that 7.4% repeated fecal testing instead of proceeding to a colonoscopy, and only 41% received a colonoscopy within one year of their initial positive test. Patients who repeated home tests cited concerns about colorectal cancer diagnosis
Studies reveal distinct differences in oral microbiomes of patients with gastric cancer, premalignant conditions, and healthy controls. Researchers also found a surge in colorectal cancer incidence among young patients under 45, while late-stage gallbladder cancer is on the rise in non-Hispanic Blacks.
A meta-analysis suggests combining microsatellite instability (MSI) and tumor-infiltrating lymphocytes (TIL) can optimize prognostic assessment in early-stage colorectal cancer. Patients with high MSI and TIL had the best prognosis, while those with low immune cells found in the tumor tissue had a poor outcome.
A study led by the University of Pennsylvania School of Medicine found that offering patients a choice between colonoscopy and at-home tests more than doubled colorectal cancer screening rates. Approximately 10% of participants received colonoscopies, while around 11% completed at-home fecal immunochemical tests.
New cancer projections highlight progress in reducing incidence rates for common cancers like lung, colorectal, and prostate, but also warn of rising rates for less common types such as liver, kidney, melanoma, and non-Hodgkin lymphoma.
Between 1999 and 2020, colorectal cancer incidence grew by 500% among children ages 10-14, 333% among teens aged 15-19, and 185% among young adults ages 20-24. Researchers highlight the need for tailored approaches to screening and awareness of signs and symptoms.
Researchers at Brigham and Women's Hospital found an association between appendix removal and a decreased risk of colorectal cancer positive for the bacterium Fusobacterium nucleatum. The study involved large prospective cohort studies and analyzed data from over 139,000 participants.
The ECOG-ACRIN Cancer Research Group has launched the ComboMATCH-E5 trial, evaluating the combination of sotorasib and panitumumab in patients with KRAS G12C-mutated advanced solid tumors. The study aims to assess the efficacy and safety of the combination in this patient population.
A study published by University of Pittsburgh researchers found that ACA insurance expansions led to an increase in patients receiving care at accredited cancer hospitals in Pennsylvania. The study suggests that these expansions make a difference in improving access to high-quality cancer care, particularly for those living in areas wi...
A cohort study found that individuals with a first colonoscopy with negative findings for colorectal cancer may benefit from longer screening intervals, potentially up to 15 years. This could lead to fewer unnecessary invasive examinations and improved patient outcomes.
Menopausal hormone therapy is appropriate to treat vasomotor symptoms in early menopause without contraindications. WHI evidence does not support routine supplementation with calcium plus vitamin D or a low-fat diet for preventing fractures and breast/colorectal cancer, respectively.
Scientists have developed mini-colon tissues that can simulate the complex process of tumorigenesis outside the body with high fidelity. These miniature organs mimic the physical structure and cellular diversity of colon tissue, allowing researchers to study colorectal cancer development and test potential therapies.
A new study reveals that aspirin boosts certain aspects of the immune system to detect and target cancer cells, reducing cancer spread to lymph nodes. Aspirin also increases expression of a protein called CD80 on immune cells, enhancing their ability to alert other immune cells of tumor-associated proteins.
A significant gap exists in the colorectal screening process, particularly after a positive stool-based test, where timely follow-up with colonoscopy is often lacking. This can lead to reduced incidence and mortality rates from colorectal cancer if addressed through education and quality measures.
The innovative Integrated Virtual Care (IVC) program successfully connected residents with family physicians in Renfrew County, addressing the rural shortage of primary care providers. Over 2,800 unique patient appointments were conducted, with 70% done virtually, offering comprehensive team-based primary care.
The study, presented at AACR Annual Meeting 2024, found the combination therapy to be effective with an objective response rate of 34% and a disease control rate of 85.1%. The regimen performed favorably compared to historical data for similar cohorts, indicating potential as a new standard of care.
Researchers developed a nanosized polymer that selectively delivers chemotherapeutic drugs to blood vessels supporting tumor growth. The treatment eliminates colorectal cancer liver metastases and prolongs mice survival after a single dose-therapy.
Researchers have identified specific gut microbiota signatures associated with KRAS mutations in colorectal cancer. The study suggests that these microbes may serve as non-invasive biomarkers for identifying subtypes of CRC and inform personalized treatment approaches.
A study of 9,740 surveillance colonoscopies found rare colorectal cancer detection and higher advanced neoplasia yields among those with prior advanced adenoma. These findings inform decision-making on continued screening in older adults with a history of colorectal adenomas.
A population-wide observational study found an association between tuberculosis (TB) and a higher incidence of various cancers. TB patients were more likely to be diagnosed with lung, blood, gynaecological, colorectal, thyroid, oesophagus, and stomach cancers compared to the general population.
A study published in the Journal of the American College of Surgeons found that hospitals accredited by the National Accreditation Program for Rectal Cancer (NAPRC) demonstrate significantly better outcomes for patients undergoing rectal cancer surgery. These institutions show lower rates of mortality, complications, and morbidity comp...